Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)

Market Cap	4.89B -4.4%
Revenue (ttm)	1.74B -17.8%
Net Income	160.68M -51.1%
EPS	0.40 -49.2%
Shares Out	404.74M
PE Ratio	30.21
Forward PE	n/a
Dividend	0.34 (2.82%)
Ex-Dividend Date	Jun 26, 2025

Volume	2,165,700
Average Volume	3,825,212
Open	12.15
Previous Close	12.07
Day's Range	12.03 - 12.15
52-Week Range	11.45 - 14.32
Beta	0.82
RSI	50.39
Earnings Date	Apr 18, 2026

About SHA:603439

Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointments. The company was founded in 1995 and is based in Anshun, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 2,852
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603439

Financial Performance

In 2024, SHA:603439's revenue was 2.14 billion, an increase of 31.16% compared to the previous year's 1.63 billion. Earnings were 274.03 million, a decrease of -6.38%.